Cel Sci Corporation (CVM)

[GD]

I told you so, CVM and Geert is a classical data mining behavior
regarding the data analysis process, good luck with fighting
with FDA for approval with subgroup efficacy data! CVM may win
or not, let see the subgroup OS KM curves first....

“...study did not achieve its primary endpoint of a 10% improvement in overall survival. However, the OS benefit of 14.1% at 5 years for the lower risk subgroup (no chemotherapy) exceeded the 10% OS benefit set out for the study population...”